Jiajin Bio
迦进生物
Jiajin Bio (迦进生物) is a Chinese biotech company developing antibody-oligo conjugate (AOC) drugs, a class of "everything conjugate" therapeutics that extends beyond the ADC format to enable targeted delivery of small nucleic acids outside the liver . FreeS Fund (峰瑞资本) was an early backer, co-leading the company's angel round with Matrix Partners China (经纬创投) and marking it as one of the first domestic ventures in this niche . The firm has since raised follow-on financing, with FreeS continuing to participate . In 2025, Jiajin Bio was listed among five FreeS portfolio companies whose founders joined the investor's managing partner Shen Jiong at a Suzhou biomedical innovation summit, signaling its standing within the firm's biotech roster .
AI-generated — may contain errors, please verify.
Coverage
3/2 Suzhou Offline Event Registration | The 4th Biomedical Innovation and Translation Summit
Exploring the Path of Innovation and Translation in Biomedicine, Together
峰瑞资本·New Listings and New Funding: 10 Developments in the Height of Summer | FreeS Family Funding News Vol.19
Looking forward to working alongside more outstanding founders.
峰瑞资本·Everything Has Two Sides: How Can "Nuclear Radiation" Be Used to Make Anti-Cancer Drugs? | FreeS Report 28
Now is the spring of radiopharmaceuticals.
峰瑞资本·Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
峰瑞资本·
